The global Diabetic Foot Ulcer Treatment Market size is expected to reach a value of USD 6.82 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.2% during the forecast period. Rising prevalence of diabetes, increasing healthcare expenses, and rapidly growing geriatric population worldwide are some of the major factors driving the diabetic foot ulcer treatment market.
Diabetic
foot ulcers are one of the most common foot injuries that is caused due to
diabetes mellitus. Management of diabetic foot ulcers aims at fast healing and
wound closure, by adopting a multidisciplinary therapeutic approach so as to
avoid amputation. Among different types of treatment options available,
biologics held the largest share in the diabetic foot ulcer treatment market in
2017. This can be attributed to strong revenue generated by growth factors that
are prescribed worldwide for their ability to promote generation of new cells
and achieve wound closure. Therapy devices and wound care dressings also offer
significant commercial opportunity due to their cost-effectiveness, ease of
availability, and wide use in combination with other treatments at every level
of wound care management.
Among
different ulcer types, neuro-ischemic ulcers led the market in 2017 with more
than 50.0% market share due to higher patient population suffering from the
ulcer type globally. North America represented the largest share in the global
market in 2017 owing to rising prevalence of diabetes, growing geriatric
cohort, increased investment in R&D of novel therapies, and developed healthcare
facilities.
Request
a free sample copy or view report summary: Diabetic Foot Ulcer Treatment Market Report
Diabetic
Foot Ulcer Treatment Market Report Highlights
- The
biologics segment commanded the largest share in 2017 and is projected to
retain its position through the forecast period, due to increased adoption
and potential approvals of growth factors
- North
America dominated the DFU treatment market in 2017 due to well-established
favorable healthcare reimbursements and infrastructure
- Asia Pacific
is expected to witness the fastest growth owing to expanding diabetes
patient population driven by increasing healthcare expenses and growing
geriatric cohort
- The
neuro-ischemic ulcers segment accounted for the leading share in 2017. It
is likely to experience the fastest growth during the forecast period
- The foam and
alginate dressings, skin grafts, and negative pressure wound therapy
segments are anticipated to exhibit significant CAGR over the forecast
period
- Some of the
key players in this space are ConvaTec, Inc.; Acelity L.P. Inc.; 3M
Healthcare; Coloplast A/S; Smith & Nephew Plc.; B. Braun Melsungen AG;
Medline Industries, Inc.; Medtronic Plc.; Organogenesis, Inc.; Molnlycke
Health Care AB; and BSN Medical GMBH.
About Us:
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, the company offers market intelligence
studies ensuring relevant and fact-based research across a range of industries
including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment